Spots Global Cancer Trial Database for Tumor RNA Transfected Dendritic Cell Vaccines

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Tumor RNA Transfected Dendritic Cell Vaccines

Official Title: Tumor RNA Transfected Dendritic Cell Vaccines

Study ID: NCT00108264

Conditions

Prostate Cancer

Interventions

Tumor RNA transfected dendritic cells

Study Description

Brief Summary: The purpose of this study is to use dendritic cells transfected with amplified RNA from autologous tumor cells to develop a vaccine strategy for the treatment of prostate cancer in patients with disseminated disease.

Detailed Description: The specific aims are: 1) to evaluate, in a phase I clinical trial, the safety of vaccinating patients with dendritic cells transfected with RNA from autologous cancer cells; 2) to analyze the T cell responses induced by the treatment; and 3) to improve the efficacy of the treatment by developing methods to increase the induction of CD4+T cell responses.